Lataa...
Sebelipase alfa for lysosomal acid lipase deficiency: 5‐year treatment experience from a phase 2 open‐label extension study
BACKGROUND AND AIMS: Lysosomal acid lipase deficiency is characterized by hepatomegaly and dyslipidaemia, which can lead to cirrhosis and premature atherosclerosis. Sebelipase alfa is an approved recombinant human lysosomal acid lipase. In an open‐label extension study of adults with lysosomal acid...
Tallennettuna:
| Julkaisussa: | Liver Int |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540377/ https://ncbi.nlm.nih.gov/pubmed/32657505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14603 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|